Dexamethasone – Page 15 – Communicable Diseases Research

Signals were broadly positive for months, but never definitive: the tocilizumab story

신호는 몇 달 동안 대체로 긍정적이었지만 결코 확정적이지 않았습니다: tocilizumab 이야기

Review

Published on 2022-03-012022-09-12
Journal: Clinical microbiology and infection : the official [Category] SARS, 신약개발, 진단,

Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?

COVID-19 환자의 신경 정신병 증상 완화 : 바이러스 성 원인 또는 약물 효과?

Article

Published on 2022-03-012022-09-12
Journal: Journal of medical virology [Category] MERS, SARS, 진단,

Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases

심장 보호 약물과 COVID-19 치료에 사용되는 약물 간의 약물 상호 작용 위험: 6개 데이터베이스의 증거 기반 검토

Review

Published on 2022-03-012022-09-11
Journal: Diabetes & metabolic syndrome [Category] SARS, 변종, 신약개발, 치료법, 치료제,

[키워드] acting antihypertensive drugs approved Atazanavir Azithromycin cardiovascular system caution Chloroquine close monitoring comorbid condition comorbid conditions Comorbidity concomitant use COVID COVID- 19 treatment COVID-19 COVID-19 infection COVID-19 treatment database Dexamethasone diabetes dosage drug drug interaction drug-drug interaction drugs Effect Effects ENhance Evidence Factor FDA glycemic control group hypertension Hypotension Improving Infection information Interaction interaction effect life Lopinavir Lopinavir/ritonavir Medicine Medscape molnupiravir monoclonal antibodies monoclonal antibody Nirmatrelvir Patient Paxlovid polypharmacy Potential Quality of life Remdesivir resulting review risk Ritonavir therapeutic efficacy therapy treating COVID-19 Treatment worsening
[DOI] 10.1016/j.dsx.2022.102451 PMC 바로가기 [Article Type] Review

Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study

Observational Study

Published on 2022-02-282022-10-04
Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상,

[키워드] 95% CI adverse outcomes age all-cause mortality Antiviral change changed Characteristics Clinical diagnosis Clinical outcome clinical outcomes Cohort cohort study cohorts COVID-19 COVID-19 patient cumulative death Decline declined Dexamethasone Electronic health records elevated Epidemiology flat hospital hospitalised hospitalised patient In-hospital In-hospital death incidence incident Laboratory Observational cohort study outcome Patient positive proportion public health remained risk secondary outcome subset the disease the median Treatment trend USA use of hydroxychloroquine with COVID-19 women
[DOI] 10.1136/bmjopen-2021-055137 PMC 바로가기 [Article Type] Observational Study

Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination

Case Reports

Published on 2022-02-262022-10-29
Journal: Infection [Category] COVID-19, COVID19(2023년), MERS, SARS, 진단,

Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial

중등도 내지 중증 CovID19 질병을 가진 입원 환자의 치료를위한 피하 Sarilumab : 실용적이고 임베디드 무작위 임상 시험

Randomized Controlled Trial

Published on 2022-02-252022-09-10
Journal: PLoS ONE [Category] 임상, 진단, 치료제,

[키워드] adaptive added addition adopted anti-IL-6R Anti-inflammatory drugs antibody Antiviral Arm benefit clinical criteria Clinical management contribute Controlled trial COVID-19 COVID-19 disease COVID19 Data monitoring committee death Dexamethasone diagnostic diagnostic test dose Effectiveness EHR Electronic health record Eligible patients evaluated event Health health record hospitalized COVID-19 patients hospitalized patient IL-6R Importance include information initial Inpatient Inpatients intubation majority measure mechanical ventilation moderate moderate to severe numbers of patient occurred Open-label outcome participant Patient patients hospitalized positive Pragmatic primary endpoint Primary outcome Probability randomization Randomized randomized clinical trial randomized trial Remdesivir respiratory respiratory compromise Result sarilumab SARS-CoV-2 setting severe COVID-19 severe COVID-19 disease Standard of care Subcutaneous subcutaneous injection the primary endpoint Treatment Trial was increased
[DOI] 10.1371/journal.pone.0263591 PMC 바로가기 [Article Type] Randomized Controlled Trial

Pneumococcal meningitis and COVID-19: dangerous coexistence. A case report

폐렴 구균 수막염 및 Covid-19 : 위험한 공존.사례 보고서

Case Reports

Published on 2022-02-232022-09-10
Journal: BMC Infectious Diseases [Category] COVID19(2023년), Fulltext, MERS, SARS, 치료기술, 치료제,

[키워드] anti-inflammatory agents anti-inflammatory treatment Antibiotic therapy Bacteria Bacterial bacterial pathogen Bacterial pathogens bleeding Blood C-reactive protein Case report ceftriaxone cerebrospinal fluid Co-infection Combination Computed tomography consciousness Corticosteroid Corticosteroids Course COVID-19 COVID-19 patient COVID-19 patients COVID-19 pneumonia Culture detect Deterioration Dexamethasone diagnosed diagnosed with COVID-19 died Diseases disorder excluded fungal infections general condition Health high-risk population Hospitalization Human Infection infections initial initial treatment intubation invasive Laboratory parameters mechanical ventilation Meningitis Mortality multiple organ failure Neurological complications Organ failure oxygen Oxygen therapy pathogen Pathogens Patient patients pneumococcal pneumococcal meningitis pneumococcal sepsis Pneumonia pneumoniae procalcitonin required respiratory Respiratory disease respiratory disorder respiratory disorders Respiratory failure responsible risk SARS-CoV-2 SARS-COV-2 infection Secondary infection secondary infections Sepsis sputum Streptococcus pneumoniae subsequent Symptom the disease the patient Tocilizumab Treatment Urine Vascular Viral viral infection viral pathogen
[DOI] 10.1186/s12879-022-07156-1 PMC 바로가기 [Article Type] Case Reports

Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile

COVID-19의 중병 예방을 위한 회복기 혈장: 2상 시험 및 면역 프로필

Clinical Trial

Published on 2022-02-232022-09-10
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료법, 치료제,

[키워드] 28-day mortality 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered administration Admission Alter anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies antibody Antibody Response Antibody titers Antiviral effect antiviral effects baseline caused circulating co-morbidities co-morbidity comparable Confirmed COVID-19 infection Control controls convalescent plasma coronavirus COVID-19 COVID-19 infection COVID-19 pandemic Critical Critical illness Critically ill death demographics Dexamethasone group hazard ratio Hospital admission ICU IgA level illness immune initial Level morbidities non-critically ill patient non-critically ill patients non-ICU pandemic Pandemics participant Patient PCR Phase 2 Planning plasma populations Preventing profile progression provide reduce reduced reduction in Remdesivir respiratory Respiratory disease Respiratory failure respiratory symptom respiratory symptoms respiratory tract SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly increased single-arm specific antibody statistically significant difference suggestion target protein target proteins tested transfer transfused transfusion Treatment Trial with COVID-19
[DOI] 10.1128/spectrum.02560-21 PMC 바로가기 [Article Type] Clinical Trial

Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV

Dexamethasone은 약물-약물 상호작용의 용량 의존적 가해자입니다.

Article

Published on 2022-02-232022-09-11
Journal: Journal of Antimicrobial Chemotherapy [Category] COVID19(2023년), SARS, 치료제,

BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant

Research

Published on 2022-02-222022-10-05
Journal: Communications Medicine [Category] 변종, 치료법,

[키워드] activate Antiviral approach Beta BNT162b2 BNT162b2 vaccine can be used clinical manifestation correlated COVID-19 patient COVID-19 patients COVID-19 symptom Dexamethasone disease severity elicit elicited ENhance first dose FIVE gene encoding gene signature hospitalized COVID-19 patient identify immune immune cells immune response increases in innate immune response molecular MONITOR naïve individual OAS of BNT162b2 Patient patients Peripheral blood Protein provide receiving Result reveal RNA sequencing RNA-Seq SARS-COV-2 infection signaling pathway the SARS-CoV-2 Transcriptome Treatment vaccination variant
[DOI] 10.1038/s43856-022-00083-x [Article Type] Research